Topics

Rocket Pharmaceuticals Receives Funding from the California Institute for Regenerative Medicine (CIRM)

07:00 EDT 30 Apr 2019 | Businesswire
This article has expired, however you can still download the PDF.
Preview:
- $6.5mm Grant to Fund U.S. Phase I/II Leukocyte Adhesion Deficiency-I Registration-Enabling Study - Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”), a leading U.S.-based multi-platform clinical-stage gene ...

Other Sources for this Article

Claudine Prowse, Ph.D.
SVP, Strategy, Corporate Development and IRO
Rocket Pharma, Inc.
The Empire State Building, Suite 7530
New York, NY 10118
www.rocketpharma.com
investors@rocketpharma.com

NEXT ARTICLE

More From BioPortfolio on "Rocket Pharmaceuticals Receives Funding from the California Institute for Regenerative Medicine (CIRM)"

Quick Search

Relevant Topics

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Gene Therapy
Gene therapy is the use of DNA as a pharmaceutical agent to treat disease. It derives its name from the idea that DNA can be used to supplement or alter genes within an individual's cells as a therapy to treat disease. The most common form of gene th...